NOVAVAX INC Retained Earnings
NOVAVAX INC (NVAX) had Retained Earnings of -$4.63 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$4.63B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$4.58B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$4.57B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$4.59B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$4.63B 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$4.58B 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$4.57B 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$4.59B 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$4.38B 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$4.49B 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$5.01B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$4.93B 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$4.81B 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$4.97B 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$4.82B 10-K · filed 2025-02-27 |
| 2023-09-30 | -$4.64B 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$4.51B 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$4.57B 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$4.28B 10-K · filed 2024-02-28 |
| 2022-09-30 | -$4.09B 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$3.93B 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$3.41B 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$3.62B 10-K · filed 2023-02-28 |
| 2021-09-30 | -$2.77B 10-Q · filed 2021-11-05 |
| 2021-06-30 | -$2.45B 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$2.10B 10-Q · filed 2021-05-10 |
| 2020-12-31 | -$1.87B 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.70B 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$1.50B 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$1.46B 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$1.43B 10-K · filed 2021-03-01 |
| 2019-09-30 | -$1.40B 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$1.38B 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$1.34B 10-Q · filed 2019-05-02 |
| 2018-12-31 | -$1.30B 10-K · filed 2020-03-11 |
| 2018-09-30 | -$1.25B 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$1.21B 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$1.16B 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$1.11B 10-K · filed 2019-03-18 |
| 2017-09-30 | -$1.06B 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$1.02B 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$974.44M 10-Q · filed 2017-05-08 |
| 2016-12-31 | -$930.00M 10-K · filed 2018-03-14 |
| 2016-09-30 | -$872.89M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$806.63M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$727.28M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$650.03M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$571.22M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$538.10M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$517.46M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$493.09M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$461.55M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$441.82M 10-Q · filed 2014-08-07 |
| 2014-03-31 | -$423.96M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$410.15M 10-K · filed 2015-02-27 |
| 2013-09-30 | -$396.09M 10-Q · filed 2013-11-12 |
| 2013-06-30 | -$380.79M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$368.16M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$358.16M 10-K · filed 2014-03-12 |
| 2012-09-30 | -$350.13M 10-Q · filed 2012-11-09 |
| 2012-06-30 | -$342.91M 10-Q · filed 2012-08-09 |
| 2012-03-31 | -$336.99M 10-Q · filed 2012-05-09 |
| 2011-12-31 | -$329.66M 10-K · filed 2013-03-12 |
| 2011-09-30 | -$325.95M 10-Q · filed 2011-11-08 |
| 2011-06-30 | -$322.74M 10-Q · filed 2011-08-09 |
| 2010-12-31 | -$310.29M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |